NexGel: $278K unrestricted cash, going-concern doubt
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
NexGel, Inc. (NXGL) reported nine-month 2026 revenue of $9.515 million, compared with $8.625 million in 2025, while net loss widened to $5.572 million from $1.965 million. It used $3.832 million in operating cash during the period and had $278,000 of unrestricted cash as of September 30, 2026. Management said these conditions raise substantial doubt about NexGel’s ability to continue as a going concern.
NexGel completed the Celularity license and asset transaction on April 17, 2026, with $13.3 million in aggregate upfront consideration: $8.3 million in cash consideration, of which $7.203 million had been paid, and a $5 million convertible note; up to $20 million in additional payments depend on commercial milestones. BioNx products generated $1.695 million in nine-month revenue. On November 10, the company closed agreements that produced approximately $1.2 million in gross proceeds; conversion of approximately $14.1 million in amended notes depends on a proposed merger, and management said these matters do not alleviate the going-concern doubt.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNine-month revenue reached $9.515 million, versus $8.625 million in 2025.
Negative
- Major pointGoing-concern doubt accompanies $278,000 unrestricted cash as of September 30, 2026.
- Moderate pointNine-month net loss widened to $5.572 million from $1.965 million.
- Moderate pointOperating cash use was $3.832 million, versus $1.592 million in 2025.
Filing Explained
The initial twelve-dollar conversion price is subject to downward resets, so it does not remain a fixed conversion price.
At
The company identifies possible default events relating to required filings and its share reserve, but reports that no noteholder had declared acceleration.
Key Figures
Key Terms
going concern financial
derivative liability financial
embedded conversion feature financial
volume-weighted average market price financial
asset acquisition financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were NXGL’s revenue and net loss for the first nine months of 2026?
Why did NXGL report substantial doubt about its ability to continue as a going concern?
What are the terms of NXGL’s April and May 2026 convertible notes?
How much could NexGel owe Celularity in milestone payments?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM
(Mark One)
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the quarterly period ended:
OR
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ___________ to ___________
Commission
file number:
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of | (I.R.S. Employer | |
| incorporation or organization) | Identification Number) |
| (Address of principal executive office) | (Zip Code) |
Registrant’s
telephone number, including area code:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The
| ||||
| The
|
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a nonaccelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ | |
| Smaller
reporting company |
Emerging
growth company |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate
by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No
As
of November 13, 2026 the registrant had
nEXGEL, INC.
TABLE OF CONTENTS
| PART I – FINANCIAL INFORMATION | ||
| ITEM 1. | Financial Statements | 3 |
| Condensed Consolidated Financial Statements (Unaudited) | 3 | |
| Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025 | 3 | |
| Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2026 and 2025 | 4 | |
| Condensed Consolidated Statements of Stockholders’ Equity for the Three and Nine Months Ended September 30, 2026 and 2025 | 5 | |
| Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2026 and 2025 | 6 | |
| Notes to Condensed Consolidated Financial Statements | 7 | |
| ITEM 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 31 |
| ITEM 3. | Quantitative and Qualitative Disclosures About Market Risk | 37 |
| ITEM 4. | Controls and Procedures | 37 |
| PART II – OTHER INFORMATION | ||
| ITEM 1. | Legal Proceedings | 38 |
| ITEM 1A. | Risk Factors | 38 |
| ITEM 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 39 |
| ITEM 3. | Defaults Upon Senior Securities | 39 |
| ITEM 4. | Mine Safety Disclosures | 39 |
| ITEM 5. | Other Information | 39 |
| ITEM 6. | Exhibits | 40 |
| Signatures | 41 | |
| 2 |
| Table of Contents |
PART I – FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
NEXGEL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF SEPTEMBER 30, 2026 AND DECEMBER 31, 2025
(Unaudited)
(in thousands, except share and per share data)
September 30, 2026 | December 31, 2025 | |||||||
| ASSETS: | ||||||||
| Current Assets: | ||||||||
| Cash | $ | $ | ||||||
| Restricted cash | ||||||||
| Accounts receivable, net | ||||||||
| Inventory, net | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Goodwill | ||||||||
| Intangibles, net | ||||||||
| Property and equipment, net | ||||||||
| Operating lease - right of use asset | ||||||||
| Investment in NexGelRx | ||||||||
| Other assets | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accounts payable - related party | ||||||||
| Accounts payable | ||||||||
| Accrued expenses and other current liabilities | ||||||||
| Current portion of note payable | ||||||||
| Partnership accrued advance | ||||||||
| Current portion of finance lease liability | ||||||||
| Current portion of operating lease liability | ||||||||
| Derivative liability, at fair value | - | |||||||
| Total current liabilities | ||||||||
| Operating lease liabilities, net of current portion | ||||||||
| Financing lease liability, net of current portion | ||||||||
| Convertible notes payable, net of debt discount | - | |||||||
| Notes payable, net of current portion | ||||||||
| Total liabilities | ||||||||
| Commitments and Contingencies (Note 16) | - | - | ||||||
| Stockholders’ Equity | ||||||||
| Preferred
stock, par value $ | - | - | ||||||
| Common
stock, par value $ | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total NexGel stockholders’ equity | ||||||||
| Non-controlling interest in joint venture | ||||||||
| Total stockholders’ equity | ||||||||
| Total liabilities and stockholders’ equity | $ | $ | ||||||
(All share and per-share amounts in these consolidated financial statements
have been retrospectively adjusted to reflect the
The accompanying notes are an integral part of these condensed consolidated financial statements.
| 3 |
| Table of Contents |
NEXGEL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025
(Unaudited)
(in thousands, except share and per share data)
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenues, net | $ | $ | $ | $ | ||||||||||||
| Cost of revenues | ||||||||||||||||
| Gross margin | ||||||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | - | |||||||||||||||
| Selling, general and administrative | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income (expense), net | ( | ) | ( | ) | ( | ) | ||||||||||
| Changes in fair value of derivative liability and warrant modification expense | ||||||||||||||||
| Loss on issuance of convertible debt | ( | ) | - | ( | ) | |||||||||||
| Other income (expense) | ||||||||||||||||
| Total other income (expense), net | ||||||||||||||||
| Loss before income taxes | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Income tax expense | - | - | - | |||||||||||||
| Net loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Less: Income attributable to non-controlling interest in joint venture | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net loss attributable to NexGel stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Net loss per common share - basic | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Net loss per common share - diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average shares used in computing net loss per common share - basic | ||||||||||||||||
| Weighted average shares used in computing net loss per common share – diluted | ||||||||||||||||
(All share and per-share amounts in these consolidated financial statements
have been retrospectively adjusted to reflect the
The accompanying notes are an integral part of these condensed consolidated financial statements.
| 4 |
| Table of Contents |
NEXGEL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025
(Unaudited)
(in thousands, except share data)
| Shares | Amount | Capital | Interest | Deficit | Equity | |||||||||||||||||||
| Common Stock | Additional Paid-in | Non- controlling | Accumulated | Total Stockholders’ | ||||||||||||||||||||
| Shares | Amount | Capital | Interest | Deficit | Equity | |||||||||||||||||||
| Balance, January 1, 2026 | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||
| Restricted stock issuances | — | — | — | |||||||||||||||||||||
| Issuance of securities for the conversion of convertible notes payable and accrued interest | — | — | — | |||||||||||||||||||||
| Net income (loss) | — | — | — | ( | ) | ( | ) | |||||||||||||||||
| Balance, March 31, 2026 | ( | ) | ||||||||||||||||||||||
| Stock-based compensation - stock options/restricted | — | — | — | — | ||||||||||||||||||||
| Issuance of securities for the conversion of convertible notes payable and accrued interest | — | — | — | |||||||||||||||||||||
| Warrants issued in conjunction with the conversion of convertible notes payable | — | — | — | — | ||||||||||||||||||||
| Net income (loss) | — | — | — | ( | ) | ( | ) | |||||||||||||||||
| Balance, June 30, 2026 | $ | ( | ) | |||||||||||||||||||||
| Stock-based compensation - stock options/restricted | — | — | — | — | ||||||||||||||||||||
| Issuance of securities for the conversion of convertible notes payable and accrued interest | — | — | — | |||||||||||||||||||||
| Warrants issued in conjunction with the conversion of convertible notes payable | — | — | — | — | ||||||||||||||||||||
| Net income (loss) | — | — | — | ( | ) | ( | ) | |||||||||||||||||
| Balance, September 30, 2026 | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||
| Common Stock | Additional Paid-in | Non- controlling | Accumulated | Total Stockholders’ | ||||||||||||||||||||
| Shares | Amount | Capital | Interest | Deficit | Equity | |||||||||||||||||||
| Balance, January 1, 2025 | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||
| Share-based compensation and restricted stock issuances | — | — | — | |||||||||||||||||||||
| Net income (loss) | — | — | — | ( | ) | ( | ) | |||||||||||||||||
| Balance, March 31, 2025 | ( | ) | ||||||||||||||||||||||
| Share-based compensation and restricted stock issuances | — | — | — | |||||||||||||||||||||
| Net income (loss) | — | — | — | ( | ) | ( | ) | |||||||||||||||||
| Balance, June 30, 2025 | ( | ) | ||||||||||||||||||||||
| Balance | ( | ) | ||||||||||||||||||||||
| Share-based compensation and restricted stock issuances | — | — | — | |||||||||||||||||||||
| Equity offering proceeds, net of stock issuance costs | — | |||||||||||||||||||||||
| Net income (loss) | — | — | — | ( | ) | ( | ) | |||||||||||||||||
| Balance, September 30, 2025 | ( | ) | ||||||||||||||||||||||
| Balance | ( | ) | ||||||||||||||||||||||
(All share and per-share amounts in these consolidated
financial statements have been retrospectively adjusted to reflect the
The accompanying notes are an integral part of these condensed consolidated financial statements.
| 5 |
| Table of Contents |
NEXGEL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025
(Unaudited)
(in thousands)
| 2026 | 2025 | |||||||
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Operating Activities | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | ||||||||
| Share-based compensation and restricted stock vesting | ||||||||
| Amortization of right-of-use asset | ||||||||
| Amortization of debt discount | — | |||||||
| Changes in fair value of warrant liability and warrant modification expense | ( | ) | ( | ) | ||||
| Loss on issuance of convertible note | - | |||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable, net | ( | ) | ||||||
| Inventory | ( | ) | ( | ) | ||||
| Prepaid expenses and other assets | ( | ) | ( | ) | ||||
| Accounts payable | ||||||||
| Accounts payable – related party | ( | ) | ( | ) | ||||
| Accrued expenses and other current liabilities | ||||||||
| Partnership advance | ( | ) | ( | ) | ||||
| Operating lease liability | ( | ) | ( | ) | ||||
| Deferred revenue | ( | ) | ||||||
| Net Cash Used in Operating Activities | ( | ) | ( | ) | ||||
| Investing Activities | ||||||||
| Capital expenditures | ( | ) | ( | ) | ||||
| Investment in BioNx (License Agreement) | ( | ) | — | |||||
| Net Cash Used in Investing Activities | ( | ) | ( | ) | ||||
| Financing Activities | ||||||||
| Proceeds from margin line of credit | — | |||||||
| Proceeds from convertible notes payable, net | ||||||||
| Proceeds from equity offerings | — | ( | ) | |||||
| Payment of contingent consideration | — | ( | ) | |||||
| Principal payment on financing lease liability | ( | ) | ( | ) | ||||
| Financing costs | ( | ) | — | |||||
| Principal payments of notes payable | ( | ) | ( | ) | ||||
| Net Cash Provided by (Used in) Financing Activities | ||||||||
| Net Increase (Decrease) in Cash * | ( | ) | ||||||
| Cash and restricted cash – Beginning of period | ||||||||
| Cash and restricted cash – End of period | $ | $ | ||||||
| (*) $ | ||||||||
| Supplemental Disclosure of Cash Flows Information | ||||||||
| Cash paid during the year for: | ||||||||
| Interest | $ | $ | ||||||
| Taxes | $ | — | $ | — | ||||
| Supplemental Non-cash Investing and Financing activities | ||||||||
| Issuance of convertible notes and other liabilities in conjunction with license agreement | $ | $ | — | |||||
| Issuance of securities for the conversion of convertible notes payable and accrued interest | $ | $ | — | |||||
| Issuance of warrants in conjunction with convertible notes payable | $ | $ | — | |||||
| Debt issued at a discount | $ | $ | — | |||||
| Derivative liabilities recognized as debt discounts | $ | $ | — | |||||
| Initial recognition of ROU asset and operating lease liabilities | $ | $ | ||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
| 6 |
| Table of Contents |
NEXGEL, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)
1. Description of Business and Basis of Presentation
NexGel, Inc. (“NexGel” or the “Company”) manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. The Company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company has historically served as a contract manufacturer, supplying our gels to third parties who incorporate them into their own products. Beginning in 2020, we created two new lines of business for the Company. First, we launched our own line of branded consumer products sold direct to consumers. Second, we expanded into custom and white label opportunities, which focuses on combining our gels with proprietary branded products and white label opportunities. All of our gel products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Together, these technologies enable us to produce gels that can satisfy rigid tolerance specifications with respect to a wide range of physical characteristics (e.g., thickness, water content, adherence, absorption, moisture vapor transmission rate a measure of the passage of water vapor through a substance and release rate) while maintaining product integrity. Additionally, we have the manufacturing ability to offer broad choices in the selection of liners onto which the gels are coated. Consequently, the Company and its customers are able to determine tolerances in moisture vapor transmission rate and active ingredient release rates while personalizing color and texture. Since April 2026, following the Company’s acquisition of an exclusive license to, and certain assets related to, Celularity Inc.’s portfolio of commercial-stage regenerative biomaterials (see “License and Acquisition of Celularity, Inc.’s Portfolio of Commercial-stage Regenerative Biomaterials” below), the Company also markets and sells biomaterial products used in tendon repair, soft tissue reconstruction and bone regeneration under the brand name “BioNx.”
NexGel was previously known as AquaMed Technologies, Inc. (“AquaMed”) before changing its name to NexGel, Inc. on November 14, 2019.
Basis of Presentation
The condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and are presented in US dollars.
The accompanying interim unaudited condensed consolidated financial statements and footnotes of NexGel have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results of the interim periods, but are not necessarily indicative of the results of operations to be anticipated for the full year ending December 31, 2026. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
Principles of Consolidation
The accompanying condensed consolidated financial statements include the accounts of the Company and the fifty percent (50%) owned CGN JV (see Note 5).
Reverse Stock Split
On
October 12, 2026, following approval by the Company’s stockholders on September 23, 2026 and its Board of Directors, the
Company effected a
License and Acquisition of Celularity, Inc.’s Portfolio of Commercial-stage Regenerative Biomaterials
On March 6, 2026, the Company entered into an Asset Purchase and Exclusive License Agreement (the “Original License Agreement”) with Celularity Inc. (“Celularity”), pursuant to which Celularity agreed to grant to the Company an exclusive perpetual license to Celularity’s commercial-stage regenerative biomaterials portfolio and certain development-stage programs and to sell to the Company assets related to the portfolio (collectively, the “Celularity Transaction”).
On April 17, 2026, the Company and Celularity entered into Amendment No. 1 to the Original License Agreement (as amended, the “License Agreement”) and concurrently closed the Celularity Transaction.
| 7 |
| Table of Contents |
Pursuant
to the License Agreement, in full consideration for the grant of rights and the transfer of assets, the Company agreed to pay or
deliver to Celularity aggregate upfront consideration of $
The products, technologies, and commercial-stage assets acquired and licensed pursuant to the License Agreement are marketed and sold by the Company under the brand name “BioNx.” References in these notes and elsewhere in this Quarterly Report on Form 10-Q to the “BioNx” line of business, “BioNx surgical” revenue, or similar terms refer to revenue and operations derived from the Celularity Transaction.
April and May 2026 Private Placement
On
or about April 17, 2026, in connection with the closing of the Celularity Transaction, the Company entered into a Securities Purchase
Agreement (the “April Purchase Agreement”) with certain accredited investors and issued (i) unsecured convertible promissory
notes (the “Notes”) in an aggregate original principal amount of $
The
Notes bear interest at
On
or about May 11, 2026, the Company issued additional Notes in an aggregate original principal amount of $
On
July 2, 2026, one of the holders of the Notes accelerated their commitment to purchase an additional $
2. Going Concern
The
accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles,
which contemplate continuation of the Company as a going concern. As of September 30, 2026, the Company had an unrestricted cash balance
of $
In
April, May and July 2026, the Company received aggregate gross proceeds of approximately $
On
November 10, 2026, the Company entered into and closed Note Amendment and Conversion Agreements with holders of approximately $
| 8 |
| Table of Contents |
We expect to continue incurring losses for the near-term future. Our ability to continue to operate as a going concern in the long-term is dependent upon our ability to manage and grow our current products and to ultimately achieve profitable operations. Management is considering various options to raise capital through equity or debt offerings to fund our current business activities and potential acquisitions. There can be no assurances, however, that management will be able to obtain sufficient additional funds, if needed, or that such funds, if available, will be obtained on terms satisfactory to us. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should we be unable to continue as a going concern. Additionally, it is reasonably possible that estimates made in the condensed consolidated financial statements have been, or will be, materially and adversely impacted in the near term as a result of these conditions, including the recoverability of long-lived assets.
3. Significant Accounting Policies and Estimates
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. These estimates and assumptions include allowances for doubtful accounts, inventory reserves, deferred taxes and related valuation allowances, share-based compensation, the valuation of the convertible notes embedded derivative liability and fair value of long-lived assets. Actual results could differ from the estimates.
Segment Reporting
The
Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 280, Segment
Reporting, requires that an enterprise report selected information about reportable segments in its financial reports issued to its
stockholders. The Company has
The NexGel segment is comprised of the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications which is based in Langhorne, Pennsylvania. The segment also includes the Kenkoderm and Silly George acquisitions and the Celularity Asset Purchase and License Agreement.
The CGN segment is comprised of the CGN JV used for the Company’s converting and packaging business, which is based in Granbury, Texas.
Reclassifications
Certain prior year amounts in the consolidated financial statements and accompanying footnotes have been reclassified to conform to the current year presentation. Specifically, deferred revenue was combined with accrued expenses and other current liabilities in the consolidated balance sheet as of December 31, 2025. In addition, the Company separately presented the amortization of the right-of-use asset and the reduction of the operating lease liability within the condensed consolidated statements of cash flows for the nine months ended September 30, 2026. These reclassifications had no effect on previously reported total assets, total liabilities, stockholders’ equity, or net loss.
Cash, Cash Equivalents and Restricted Cash
Cash is comprised of cash in banks. The Company considers highly liquid investments, including U.S. treasury bills purchased with an original maturity of three months or less as well as investments in money market funds for which the carrying amount approximates fair value, due to the short maturities of these investments to be cash equivalents. As of September 30, 2026 and December 31, 2025, the Company had no cash equivalents.
The
Company also maintains restricted cash under a Partnership Agreement (see Note 16). As of September 30, 2026, restricted cash totaled
$
Schedule of Cash and Cash Equivalents
| September 30, | September 30, | |||||||
| 2026 | 2025 | |||||||
| Cash | $ | $ | ||||||
| Restricted cash | ||||||||
| Total cash and restricted cash shown in the statement of cash flows | $ | $ | ||||||
| 9 |
| Table of Contents |
Accounts Receivable, Net
Trade
accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company evaluates the
collectability of accounts receivable and records a provision to the allowance for credit losses based on factors including the
length of time the receivables are past due, the customer’s payment history, the credit quality of the customer and other
factors that may affect the customers’ ability to pay. Provisions to the allowances for credit losses are recorded in selling,
general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable
will not be recovered. The allowance for credit losses was $
Inventory and Cost of Revenues
The
inventory balance is stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. The
Company evaluates inventories for excess quantities, obsolescence, and shelf-life expiration. This evaluation includes an analysis of
historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products,
general market conditions, and a review of the shelf-life expiration dates for products. These factors determine when, and if, the Company
adjusts the carrying value of inventory to estimated net realizable value. The reserve recorded against inventories was $
The Company produces proprietary branded products and white label opportunities in our manufacturing of consumer products. In our contract manufacturing, the Company builds its products based on customer orders and immediately ships the products upon completion of the production process.
The inventory balance is made up of raw materials, work-in-progress, and finished goods. Inventory is maintained at the Company’s warehouses, third party warehouses and at fulfilment centers owned by Amazon.
The “Cost of revenues” line item in the condensed consolidated statements of operations is comprised of the book value of inventory sold to customers during the reporting period. When circumstances dictate that we use net realizable value as the basis for recording inventory, we base our estimates on expected future selling prices less expected disposal costs.
Research and Development
Our research and development activities focus on new and innovative products designed to support revenue growth. Research and development expenses consist primarily of contracted development and testing efforts associated with development of products. Research and development costs are expensed as incurred.
Property and Equipment, Net
Property and equipment is recorded at historical cost, net of accumulated depreciation and amortization. Depreciation is provided over the assets’ useful lives on a straight-line basis. Leasehold improvements and right-of-use assets under financing lease arrangements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. Repairs and maintenance costs are expensed as incurred.
Management periodically assesses the estimated useful life over which assets are depreciated or amortized. If the analysis warrants a change in the estimated useful life of property and equipment, management will reduce the estimated useful life and depreciate or amortize the carrying value prospectively over the shorter remaining useful life.
The carrying amounts of assets sold or retired and the related accumulated depreciation are eliminated in the year of disposal and any resulting gains and losses are included in the results of operations during the same year.
| 10 |
| Table of Contents |
Impairment of Long-Lived Assets
The Company reviews its property and equipment and any identifiable intangibles with definite lives for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flow expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.
Goodwill and Intangible Assets
In applying the acquisition method of accounting, amounts assigned to identifiable assets and liabilities acquired were based on estimated fair values as of the date of acquisition, with the remainder recorded as goodwill. Identifiable intangible assets are initially recorded at fair value using generally accepted valuation methods appropriate for the type of intangible asset. Identifiable intangible assets with definite lives are amortized over their estimated useful lives and are reviewed for impairment if indicators of impairment arise. Intangible assets with indefinite lives are tested for impairment within one year of the acquisition date or annually as of December 31, and whenever indicators of impairment exist. The fair value of intangible assets is compared with their carrying values, and an impairment loss would be recognized for the amount by which carrying amount exceeds its fair value.
Prepaid Expenses and Other Current Assets
Prepaid
expenses and other current assets are recorded at historical cost and are primarily made up of $
Other Assets
Other assets are recorded at historical costs, and as of September 30, 2026 and December 31, 2025, the balance is primarily comprised of spare parts for manufacturing equipment. The Company maintains spare parts for either repair and maintenance, which is expensed as incurred, or replacement of capitalized equipment. Capitalized equipment spare parts are not subject to depreciation until such time that they are placed into service and the part that is being replaced is disposed.
Fair Value Measurements
The Company utilizes the fair value hierarchy to apply fair value measurements. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair values that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below:
Level 1 —Quoted prices for identical assets or liabilities in active markets.
Level 2 —Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable.
Level 3 —Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable.
The Company considers the carrying amounts of its financial instruments (cash, accounts receivable and accounts payable, notes payable and convertible notes payable) in the condensed consolidated balance sheet to approximate fair value because of the short-term or highly liquid nature of these financial instruments.
| 11 |
| Table of Contents |
In
2025, the Company estimated the fair value of its investment in NexGelRX to be $
Derivative Liabilities
The Company measures certain liabilities at fair value on a recurring basis. These liabilities consist primarily of derivative liabilities associated with convertible notes (see Note 13). These instruments are valued using significant unobservable inputs and are classified within Level 3 of the fair value hierarchy. The fair value of these instruments was updated as of September 30, 2026 in accordance with ASC 820, Fair Value Measurement, reflecting all relevant market inputs and valuation considerations as of the reporting date.
Valuation Methodology
The derivative liabilities relate to embedded features within the Company’s convertible notes, including variable conversion pricing. Because these features are not considered indexed to the Company’s own stock and may require net-cash settlement, they are accounted for as derivative liabilities under ASC 815, Derivatives and Hedging—Contracts in Entity’s Own Equity.
The Company engaged an independent valuation specialist to estimate the fair value of the derivative liabilities using a Monte Carlo simulation model, which incorporates assumptions regarding expected volatility, risk-free interest rates, expected term, and probability-weighted assessments of contingent events. The derivative liability was estimated based on Level 3 inputs.
Fair Value Hierarchy
Schedule of Fair Value of Derivative Liabilities
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| Derivative liability as of September 30, 2026 ($ in thousands) | $ | – | $ | – | $ | $ | ||||||||||
Level 3 Roll-forward
Schedule of Level 3 Roll-forward for Derivative Liabilities
| Amount ($ in thousands) | ||||
| Balance at January 1, 2026 | $ | – | ||
| Initial recognition of derivative liability | ||||
| Changes in fair value | ( | ) | ||
| Balance at September 30, 2026 | $ | |||
Equity Classified Warrants
Warrants that meet all necessary criteria to be accounted for as equity in accordance with ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, are presented within additional paid-in capital within the Company’s consolidated statements of changes in stockholders’ equity and consolidated balance sheets. Warrants classified as equity are initially measured at fair value using a Black-Scholes option valuation model. Subsequent changes in fair value are not recognized as long as the warrants continue to be classified as equity.
Offering Costs
The Company complies with the requirements of ASC 340-40, Other Assets and Deferred Cost, with regards to offering costs. Prior to the completion of an offering, offering costs will be capitalized as deferred offering costs on the balance sheet. The deferred offering costs will be charged to stockholders’ equity upon the completion of an offering or to expense if the offering is not completed.
| 12 |
| Table of Contents |
Revenue Recognition
The Company records revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.
The Company currently recognizes revenue predominately from four sources: contract manufacturing, custom and white label finished goods manufacturing (“Custom and white label”), our branded consumer products and biomaterial products. Contract manufacturing, custom and white label, and biomaterial product revenues are recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time the customer receives the product. Branded consumer product revenue is derived from direct-to-consumer purchases through websites like Amazon and through our Shopify stores. Revenue is recognized upon shipment to the end customer.
The Company’s customers consist of other life sciences companies and Amazon retail customers. Revenues are predominately concentrated in the United States, but with the Silly George acquisition, have expanded into Europe and Asia. Payment terms, excluding branded consumer products, vary by the type and location of customer and may differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 60 days from date of shipment. Branded consumer products are purchased and paid for by the consumer at the time the transaction is completed.
Estimates for product returns, allowances and discounts are recorded as a reduction of revenue and are established at the time of sale. Returns are estimated through a comparison of historical return data and are determined for each product and adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have not been material. Amounts accrued for sales allowances and discounts are based on estimates of amounts that are expected to be claimed on the related sales and are based on historical data. Payments for allowances and discounts have historically been immaterial.
| 13 |
| Table of Contents |
The Company has five distinct lines of business; Contract Manufacturing, Custom and White Label, Consumer Branded Products, Biomaterial products and Medical Devices/Other.
Contract Manufacturing
Customers order rolls of gel (“rollstock”). The rollstock is shipped to our customers, which they package into finished goods. Historically, this has been the Company’s primary source of revenue.
Custom and White Label
These products often infuse various ingredients into our base gel to develop unique product offerings to satisfy market demand (e.g. aloe infused into the gel for a beauty mask). The rollstock is converted and packaged into salable units. The finished goods are shipped to the customer, who is ultimately responsible for product distribution. Frequently these products started as development deals, in which the customer paid the Company a small fee to develop a specific product. Once completed, the customer places an order for newly developed product.
Consumer Branded Products
These products are finished goods marketed and sold directly to consumers by the Company through online and retail channels. We are responsible for sales, marketing, and distribution. The products we sell under our MedaGel brand primarily relate to healthcare over-the-counter (“OTC”) remedy solutions, such as blister and pain applications. In December 2023 we added a second consumer product brand when we completed the purchase of the Kenkoderm brand. The Kenkoderm skincare line was originally developed by a dermatologist to provide gentle to the skin products for consumer with psoriasis. In May 2024, we added our third consumer product brand with the purchase of the Silly George brand. Silly George is a beauty brand primarily focused on false eyelashes and other eye related products. We continue to look for additional potential acquisitions as part of our consumer product “roll-up” strategy.
Biomaterial Products
These finished goods products are licensed as a result of the Celularity transaction, disclosed in Note 1, and establishes the Company as an emerging platform in regenerative medicine through the formation of BioNx Surgical, a dedicated division focused on advanced biomaterials for tendon repair, soft tissue reconstruction, and bone regeneration. The acquired portfolio includes 6 established products with over a decade of clinical use and existing reimbursement coverage. We are responsible for sales, marketing and distribution.
Medical Devices/Other
Medical Devices are a hybrid business, combining elements of Custom & White Label and Consumer Branded Products. Medical Devices, which are not yet marketed, are expected to be distributed through strategic partnerships. We will manufacture and possibly convert/package the device while the strategic partner brings the product to market. Small market Medical Devices could be launched by us, but also be offered to a distributor to reach the full scale of the market.
Other includes freight charged to customers who purchase the Company’s branded consumer products through their Shopify stores.
Disaggregated revenue by sales type ($ in thousands):
Schedule of Disaggregated Revenue by Sales Type
| 2026 | 2025 | |||||||
| Three Months | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| Contract manufacturing | $ | $ | ||||||
| Custom and white label finished goods manufacturing | - | - | ||||||
| Consumer branded products | ||||||||
| Medical devices/other | ||||||||
| Biomaterial products | - | |||||||
| Total | $ | $ | ||||||
| 2026 | 2025 | |||||||
| Nine Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| Contract manufacturing | $ | $ | ||||||
| Custom and white label finished goods manufacturing | - | |||||||
| Consumer branded products | ||||||||
| Medical devices/other | ||||||||
| Biomaterial products | - | |||||||
| Total | $ | $ | ||||||
| 14 |
| Table of Contents |
Shipping and Handling Revenue and Expense
Shipping and handling revenue and expense are included in our condensed consolidated statements of operations in revenues and cost of revenues, respectively. The Company accounts for shipping activities, consisting of direct costs to ship products performed after the risk of loss passes to the customer. Shipping revenue and expense are primarily generated through the Amazon marketplace and Silly George direct customer sales.
Share-based Compensation
On August 28, 2019, the Company adopted the 2019 Long-Term Incentive Plan, as amended (the “2019 Plan”). See Note 15 for further details regarding the 2019 Plan.
The 2019 Plan provides certain employees, contractors, and outside directors with share-based compensation in the form of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights and other awards. The fair values of incentive stock option award grants are estimated as of the date of grant using a Black-Scholes option valuation model. Compensation expense is recognized in the condensed consolidated statements of operations on a straight-line basis over the requisite service period, which is generally the vesting period.
Income Taxes
Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax bases of assets and liabilities at the applicable tax rates. Deferred tax assets are reduced by a valuation allowance when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates.
Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by a tax authority and based upon the technical merits of the tax position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. An unrecognized tax benefit, or a portion thereof, is presented in the consolidated financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed.
Leases
We account for our leases in accordance with ASC 842, Leases. We determine whether an arrangement is an operating or financing lease at contract inception. Operating leases, requires recognition of leases on the consolidated balance sheets as right-of-use (“ROU”) assets and lease liabilities. ROU assets represent the Company’s right to use underlying assets for the lease terms and lease liabilities represent the Company’s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. As the Company’s leases do not provide an implicit rate, the Company used its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. A number of the lease agreements contain options to renew and options to terminate the leases early. The lease term used to calculate ROU assets and lease liabilities only includes renewal and termination options that are deemed reasonably certain to be exercised.
The Company recognized lease liabilities, with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months. The ROU assets were adjusted pursuant to ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, and unamortized lease incentives provided by lessors. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in cost of revenues and selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the year when the changes in facts and circumstances on which the variable lease payments are based occur. The Company has elected not to separate lease and non-lease components for all property leases for the purposes of calculating ROU assets and lease liabilities.
| 15 |
| Table of Contents |
Financing leases are those that transfer substantially all of the risks and rewards of ownership to the Company. At the lease commencement date, the Company recognizes a financing lease ROU asset and a corresponding lease liability measured at the present value of future lease payments. The ROU asset is subsequently amortized on a straight-line basis over the shorter of the lease term or the useful life of the underlying asset, while the lease liability is increased by interest expense and reduced by lease payments made. Interest expense on the lease liability and amortization of the ROU asset are presented separately in the consolidated statements of operations, resulting in a front-loaded expense pattern over the lease term. Financing lease ROU assets are included in property and equipment, net, and the related lease liabilities are included within current and long-term liabilities, as applicable.
Variable Interest Entity
The Company reviews each legal entity formed by parties related to the Company to determine whether or not the Company has a variable interest in the entity and whether or not the entity would meet the definition of a variable interest entity (“VIE”) in accordance with ASC Topic 810, Consolidation. In assessing whether the Company has a variable interest in the entity as a whole, the Company considers and makes judgements regarding the purpose and design of the entity, the value of the licensed assets to the entity, the value of the entity’s total assets and the significant activities of the entity. If the Company has a variable interest in the entity as a whole, the Company assesses whether or not the Company is a primary beneficiary of that VIE, based on a number of factors, including: (i) which party has the power to direct the activities that most significantly affect the VIE’s economic performance, (ii) the parties’ contractual rights and responsibilities pursuant to the collaboration agreement, and (iii) which party has the obligation to absorb losses of or the right to receive benefits from the VIE that could be significant to the VIE.
If the Company determines that it is the primary beneficiary of a VIE at the onset of the collaboration, the collaboration is treated as a business combination and the Company consolidates the financial statements of the VIE into the Company’s consolidated financial statements. On a quarterly basis, the Company will evaluate whether it continues to be the primary beneficiary of the consolidated VIE. If the Company determines that it is no longer the primary beneficiary of a consolidated VIE, it deconsolidates the VIE in the period in which the determination is made.
Assets and liabilities recorded as a result of consolidating the financial results of the VIE into the Company’s consolidated balance sheet do not represent additional assets that could be used to satisfy claims against the Company’s general assets or liabilities for which creditors have recourse to the Company’s general assets.
Accounting Pronouncements Issued But Not Yet Adopted
In December 2025, the FASB issued ASU 2025-12, Codification Improvements to make improvements to the Codification arising from technical corrections, unintended application of the Codification, and clarifications. For all entities, the amendments in this Update are effective for annual reporting periods beginning after December 15, 2026, including interim periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact this new guidance will have on its financial statements and disclosures.
In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-04) Disaggregation of Income Statement Expenses, which requires additional disclosure of the nature of expenses included in the income statement in response to requests from investors for more information about an entity’s expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The guidance is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. Early adoption is permitted. The Company is currently evaluating the impact this new guidance will have on its financial statements and disclosures.
| 16 |
| Table of Contents |
4. Business Segments
The Company’s CODM evaluates the financial performance of the Company’s segments based upon segment operating income or (loss) as the profitability measure. The Company has identified its Chief Executive Officer as the CODM. Items outside of operating income or (loss) are not reported by segment, since they are excluded from the single measure of segment profitability reviewed by the CODM.
Summarized financial information concerning the Company’s reportable segments for each of the quarters ended September 30, 2026 and 2025 is presented below.
Schedule of Reportable Segments
Three Months Ended September 30, 2026 ($ in thousands)
| NexGel | CGN JV | Total | ||||||||||
| Revenues, net | $ | $ | $ | |||||||||
| Cost of revenues | ||||||||||||
| Advertising, marketing and amazon fees | - | |||||||||||
| General and administrative | ||||||||||||
| Total Selling, general and administrative | ||||||||||||
| Research and development | - | - | - | |||||||||
| Operating expenses | ||||||||||||
| Income (loss) from operations | $ | ( | ) | $ | $ | ( | ) | |||||
Three Months Ended September 30, 2025 ($ in thousands)
| NexGel | CGN JV | Total | ||||||||||
| Revenues, net | $ | $ | $ | |||||||||
| Cost of revenues | ||||||||||||
| Advertising, marketing and amazon fees | - | |||||||||||
| General and administrative | ||||||||||||
| Total Selling, general and administrative | ||||||||||||
| Research and development | - | |||||||||||
| Operating expenses | ||||||||||||
| Income (loss) from operations | $ | ( | ) | $ | $ | ( | ) | |||||
| 17 |
| Table of Contents |
Nine Months Ended September 30, 2026 ($ in thousands)
| NexGel | CGN JV | Total | ||||||||||
| Revenues, net | $ | $ | $ | |||||||||
| Cost of revenues | ||||||||||||
| Advertising, marketing and amazon fees | - | |||||||||||
| General and administrative | ||||||||||||
| Total Selling, general and administrative | ||||||||||||
| Research and development | - | |||||||||||
| Operating expenses | ||||||||||||
| Income (loss) from operations | $ | ( | ) | $ | $ | ( | ) | |||||
Nine Months Ended September 30, 2025 ($ in thousands)
| NexGel | CGN JV | Total | ||||||||||
| Revenues, net | $ | $ | $ | |||||||||
| Cost of revenues | ||||||||||||
| Advertising, marketing and amazon fees | - | |||||||||||
| General and administrative | ||||||||||||
| Total Selling, general and administrative | ||||||||||||
| Research and development | - | |||||||||||
| Operating expenses | ||||||||||||
| Income (loss) from operations | $ | ( | ) | $ | $ | ( | ) | |||||
Summarized total assets for the Company’s reportable segments as of September 30, 2026 and December 31, 2025 are presented below:
As of September 30, 2026 ($ in thousands)
| NexGel | CGN JV | Total | ||||||||||
| Total Assets | $ | $ | $ | |||||||||
As of December 31, 2025 ($ in thousands)
| NexGel | CGN JV | Total | ||||||||||
| Total Assets | $ | $ | $ | |||||||||
| 18 |
| Table of Contents |
5. Variable Interest Entities
Interest in Joint Venture – CGN
On
March 1, 2023, the Company acquired a
The CGN JV is considered to be a VIE and we have consolidated the CGN JV, because we believe we are the primary beneficiary and we meet the power and the economics criteria.
The following table presents the assets and liabilities of the CGN JV, included in the condensed consolidated balance sheet as of September 30, 2026 and December 31, 2025. The assets and liabilities presented below include only the third-party assets and liabilities of the consolidated VIE and excludes any intercompany balances, which were eliminated upon consolidation.
Schedule of Consolidated Variable Interest Entities
| September 30, 2026 | December 31, 2025 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash | $ | $ | ||||||
| Accounts receivable, net | ||||||||
| Inventory | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Intangibles, net | ||||||||
| Property and equipment, net | ||||||||
| Operating lease - right of use asset | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accounts payable – related party | ||||||||
| Accounts payable | ||||||||
| Accrued expenses and other current liabilities | - | |||||||
| Current portion of note payable | ||||||||
| Finance lease liability, short term | ||||||||
| Operating lease liability, current portion | ||||||||
| Total current liabilities | ||||||||
| Operating lease liability, net of current portion | ||||||||
| Finance lease liability, long term | ||||||||
| Notes payable, net of current portion | ||||||||
| Total liabilities | $ | $ | ||||||
The amounts above represent the assets and liabilities of the VIE described above, for which we are the primary beneficiary. The assets of the CGN JV consolidated VIE can only be used to settle the obligations of the VIE. All of the liabilities are non-recourse to us as of September 30, 2026 and December 31, 2025.
| 19 |
| Table of Contents |
6. Operating Leases
The
Company has an operating lease for a commercial manufacturing facility and administrative offices located in Langhorne, Pennsylvania
that runs through January 2031.
The Company also has a sublease for office and manufacturing space in Granbury, Texas that runs through February 2028. The Company modified the lease agreement through July 2035.
On
April 17, 2026, in conjunction with the Celularity License Agreement, the Company entered into a five-year sublease with Celularity,
Inc. for approximately
The following table presents information about the amount and timing of the liability arising from the Company’s operating lease as of September 30, 2026 ($ in thousands):
Schedule of Future Minimum Operating Lease Payments
| Maturity of Lease Liability | Operating Lease Liability | |||
| 2026 | $ | |||
| 2027 | ||||
| 2028 | ||||
| 2029 | ||||
| 2030 | ||||
| Thereafter | ||||
| Total undiscounted operating lease payments | ||||
| Less: Imputed interest | ( | ) | ||
| Present value of operating lease liability | $ | |||
Total
operating lease expense for the nine months ended September 30, 2026, and 2025, was $
Supplemental cash flows information related to leases was as follows:
Schedule of Supplemental Cash Flows Information Related to Operating Leases
| September 30, | September 30, | |||||||
| 2026 | 2025 | |||||||
| Cash paid for amounts included in the measurement of lease liability ($ in thousands): | ||||||||
| Operating cash flows from operating leases | $ | $ | ||||||
7. Financing Lease
In
February 2024, the CGN JV entered into a lease agreement for certain equipment under separate non-cancelable equipment loan and security
agreements. The agreement matures in January 2030. The agreements require monthly payments of principal and interest through maturity
and are secured by the assets under the lease. As of September 30, 2026, $
| 20 |
| Table of Contents |
The following table presents information about the amount and timing of the liability arising from the Company’s financing lease as of September 30, 2026:
Schedule of Future Minimum Financing Lease Payments
| Maturity of Lease Liability | Financing Lease Liability | |||
| 2026 | $ | |||
| 2027 | ||||
| 2028 | ||||
| 2029 | ||||
| Thereafter | ||||
| Total undiscounted financing lease payments | ||||
| Less: Imputed interest | ( | ) | ||
| Present value of financing lease liability | $ | |||
Supplemental cash flows information related to financing lease was as follows:
Schedule of Supplemental Cash Flows Information Related to Financing Lease
| September 30, | September 30, | |||||||
| 2026 | 2025 | |||||||
| Cash paid for amounts included in the measurement of lease liability ($ in thousands): | ||||||||
| Financing cash flows from financing lease | $ | $ | ||||||
8. Inventory, net
Inventory consists of the following ($ in thousands):
Schedule of Inventory
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Raw materials | $ | $ | ||||||
| Work-in-progress | ||||||||
| Finished goods | ||||||||
| Inventory, gross | ||||||||
| Less: Inventory reserve for excess and slow moving inventory | ( | ) | ( | ) | ||||
| Total | $ | $ | ||||||
Inventory is maintained at the Company’s warehouses and at fulfillment centers owned by Amazon and Borderless. The Company builds its contract manufacturing products based on customer orders and immediately ships the products upon completion of the production process.
9. Property and Equipment, Net
Property and equipment consist of the following ($ in thousands):
Schedule of Property and Equipment
| Useful Life | September 30, | December 31, | ||||||||||
| (Years) | 2026 | 2025 | ||||||||||
| Machinery and equipment | $ | $ | ||||||||||
| Office furniture and equipment | ||||||||||||
| Leasehold improvements | ||||||||||||
| Construction in progress | N/A | |||||||||||
| Property and equipment, gross | ||||||||||||
| Less: accumulated depreciation and amortization | ( | ) | ( | ) | ||||||||
| Property and equipment, net | $ | $ | ||||||||||
Depreciation
expense for the nine months ended September 30, 2026 and 2025 was $
| 21 |
| Table of Contents |
10. Intangible Assets
The following provides a breakdown of identifiable intangible assets as of September 30, 2026 and December 31, 2025:
Schedule of Breakdown of Identifiable Intangible Assets
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| License Agreement | ||||||||
| License agreement, gross | $ | $ | - | |||||
| Accumulated amortization | ( | ) | - | |||||
| License agreement related identifiable intangible assets, net | - | |||||||
| Product/Technology Related | ||||||||
| Identifiable intangible assets, gross | ||||||||
| Accumulated amortization | ( | ) | ( | ) | ||||
| Product/technology related identifiable intangible assets, net | ||||||||
| Marketing Related | ||||||||
| Customer related intangible asset, gross | ||||||||
| Tradename related intangible asset, gross | ||||||||
| Accumulated amortization | ( | ) | ( | ) | ||||
| Marketing related identifiable intangible assets, net | ||||||||
| Total identifiable intangible assets, net | $ | $ | ||||||
As
discussed in Note 1, on April 17, 2026, the Company completed the acquisition of an exclusive license and certain related assets from
Celularity pursuant to the License Agreement. The Company accounted for the transaction as an asset acquisition and recorded a finite-lived
intangible asset with an initial carrying value of $
In
connection with the May 15, 2024 acquisition of Silly George, the Company identified intangible assets of $
The
intangible assets with definite lives are being amortized on a straight-line basis over their weighted average estimated useful life
of
As of September 30, 2026, the estimated annual amortization expense for each of the next five fiscal years is as follows ($ in thousands):
Schedule of Estimated Annual Amortization Expense
| 2026 (remainder of year) | $ | |||
| 2027 | ||||
| 2028 | ||||
| 2029 | ||||
| 2030 | - | |||
| Subtotal | ||||
| Indefinite lived intangible assets (subject to impairment analysis) | ||||
| Total | $ |
11. Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consist of the following ($ in thousands):
Schedule of Accrued Expenses and Other Current Liabilities
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Salaries, benefits, and incentive compensation | $ | $ | ||||||
| Other | ||||||||
| Total accrued expenses and other current liabilities | $ | $ | ||||||
| 22 |
| Table of Contents |
12. Notes Payable
CGN Segment
The
CGN JV has entered into two separate promissory note agreements for the purchase of equipment. These notes have a term of
NexGel Segment
The
Company has entered into a $
Economic Injury Disaster Loan
On
May 28, 2020, the Company entered into the standard loan documents required for securing a loan (the “EIDL Loan”) from the
SBA under its Economic Injury Disaster Loan (“EIDL”) assistance program in light of the impact of the COVID-19 pandemic on
the Company’s business. Pursuant to that certain Loan Authorization and Agreement (the “SBA Loan Agreement”), the principal
amount of the EIDL Loan is up to $
The future annual principal amounts and accrued interest to be paid as of September 30, 2026 are as follows:
Schedule of Debt Instruments
| Amount | ||||
| For the year ending December 31 | ||||
| 2026 | $ | |||
| 2027 | ||||
| 2028 | ||||
| 2029 | ||||
| 2030 | ||||
| Thereafter | ||||
| Total | ||||
| Less: current portion of notes payable | ||||
| Long-term portion of notes payable | $ | |||
13. Convertible Notes Payable
Series A Convertible Notes
On
February 10, 2026, the Company issued $
The
holder may convert the Series A Convertible Note or any portion of the Series A Convertible Note, at their option, into common shares
of the Company. The number of common shares to be issued will equal 110% of outstanding principal and accrued unpaid interest converted
at the conversion price of $
| 23 |
| Table of Contents |
The
Series A Convertible Note was issued at a $
During
the nine months ending September 30, 2026, the holder converted $
On August 12, 2026, the remaining restricted cash was applied to the outstanding obligations under the Series A Convertible Note. As a result, the Series A Convertible Note has been paid in full and the Company no longer has any obligation to make payments or issue shares of common stock. The related security documents have terminated in accordance with their terms, and the related security interests have been released.
Convertible Promissory Notes
As
discussed in Note 1, in April and May 2026, to fund the license and acquisition of Celularity Inc.’s portfolio of commercial-stage
regenerative biomaterials, the Company issued $
The
notes are convertible at the option of the holder into shares of the Company’s common stock at an initial conversion price of $
The notes contain customary events of default, mandatory prepayment provisions from certain financing proceeds, and optional prepayment provisions requiring payment of a premium. The financing agreements also include registration rights, rights of first refusal, restrictions on certain future financing transactions, and other customary investor protections.
The Company is aware that potential events of default may exist under the Notes issued in April and May 2026, relating to (i) the Company’s not having filed the registration statement required under the related Registration Rights Agreement within the time period specified therein, (ii) the Company’s not having timely filed a Current Report on Form 8-K/A containing certain financial statements required under Item 9.01 of Form 8-K in connection with the Celularity Transaction, and (iii) the sufficiency of the Company’s reserve of authorized and unissued shares of common stock for issuance upon conversion of the Notes and exercise of the related warrants. No holder of the Notes has declared an acceleration of the Notes or the amounts payable thereunder. The Company has taken steps intended to address these matters, including filing on August 20, 2026 a registration statement on Form S-1 covering the resale of shares of common stock issuable upon conversion of the Notes (other than Notes held by certain officers and directors), which has not yet been declared effective, working with Celularity toward the filing of the Form 8-K/A, which the Company expects to file following the filing of this Quarterly Report on Form 10-Q, and obtaining stockholder approval on September 23, 2026 of an increase in the Company’s authorized shares of common stock and a reverse stock split, which reverse stock split was effected on October 12, 2026. In addition, the Note Amendment and Conversion Agreements described in Note 19 include waivers by the holders party thereto of these matters. There can be no assurance that these matters will be resolved on terms satisfactory to the Company, or at all.
| 24 |
| Table of Contents |
In
connection with the issuance of the convertible notes, the Company also issued
The Company evaluated the warrants under ASC 815-40 and concluded that they meet the requirements for equity classification. Accordingly, the warrants were recorded in additional paid-in capital and are not subsequently remeasured.
The Company evaluated the conversion feature of the notes under ASC 815, Derivatives and Hedging, and determined that the conversion feature does not qualify for the scope exception in ASC 815-40 due primarily to the full-ratchet anti-dilution provisions and automatic conversion price reset features, which could result in a settlement amount that is not indexed solely to the Company’s own stock.
Accordingly,
the Company bifurcated the embedded conversion feature from the host debt instrument and recorded it as a derivative liability at fair
value on the issuance date. The initial fair value assigned to the derivative reduced the carrying amount of the host debt and is subsequently
remeasured to fair value at each reporting date, with changes in fair value recognized in the consolidated statements of operations until
the derivative is exercised, expires, or is otherwise extinguished. Upon initial recognition, the Company recognized a day-one loss of
$
In
connection with the issuance of the convertible debt, the Company issued a placement agent warrant to purchase
On
July 2, 2026, one of the holders of the Notes accelerated their commitment to purchase an additional $
In
connection with the issuance of the convertible notes, the Company also issued
The Company evaluated the warrants under ASC 815-40 and concluded that they meet the requirements for equity classification. Accordingly, the warrants were recorded in additional paid-in capital and are not subsequently remeasured.
Accordingly,
the Company bifurcated the embedded conversion feature from the host debt instrument and recorded it as a derivative liability at fair
value on the issuance date. The initial fair value assigned to the derivative reduced the carrying amount of the host debt and is subsequently
remeasured to fair value at each reporting date, with changes in fair value recognized in the consolidated statements of operations until
the derivative is exercised, expires, or is otherwise extinguished. Upon initial recognition, the Company recognized a day-one loss of
$
As
of September 30, 2026, the Convertible Promissory Notes had principal outstanding of $
| 25 |
| Table of Contents |
The components of the Company’s outstanding convertible debt as of September 30, 2026 were as follows ($ in thousands):
Schedule of Outstanding Convertible Debt
| September 30, 2026 | ||||
| Series A Convertible Note | $ | - | ||
| Convertible Promissory Notes | ||||
| Total gross principal | ||||
| Unamortized debt discount and OID – Convertible Promissory Notes | ( | ) | ||
| Total principal, net of unamortized debt discount | ||||
| Accrued interest | ||||
| Convertible debt, long-term, net of debt discount | $ | |||
14. Common Stock
At September 30, 2026, the Company has reserved common stock for issuance in relation to the following:
Schedule of Reserved Common Stock For Issued Securities in Relation
| Share-based compensation plan | ||||
| Warrants to purchase common stock | ||||
| Restricted stock units |
15. Share-based Compensation
The
2019 Plan provides for the granting of incentive stock options, nonqualified stock options, restricted stock, stock appreciation rights
(“SARs”), restricted stock units, performance awards, dividend equivalent rights and other awards, which may be granted singly,
in combination, or in tandem, and which may be paid in cash, shares of common stock of the Company or a combination of cash and shares
of common stock of the Company. Effective as of May 26, 2020, May 3, 2021, and March 23, 2023 respectively, the Board approved an increase
of the number of authorized shares of common stock reserved under the 2019 Plan from
On
December 31, 2024, the Board approved an additional
The following table contains information about the 2019 Plan as of September 30, 2026:
Schedule of Information about Incentive Plan
| Awards | Awards | |||||||||||||||
| Reserved for | Awards | Awards | Available for | |||||||||||||
| Issuance | Issued | Exercised | Grant | |||||||||||||
| 2019 Plan(1) | ||||||||||||||||
| Awards issued in excess of 2019 Plan(2) | - | - | ||||||||||||||
| (1) | |
| (2) |
Incentive stock options
On
April 27, 2026, the Company granted options to purchase up to
| 26 |
| Table of Contents |
On
February 12, 2026, the Company granted options to purchase up to
The following table summarizes the Company’s incentive stock option activity and related information for the nine months ended September 30, 2026:
Schedule of Incentive Stock Option Activity
| Weighted | ||||||||||||
| Weighted | Average | |||||||||||
| Average | Contractual | |||||||||||
| Number of | Exercise | Term in | ||||||||||
| Options | Price | Years | ||||||||||
| Outstanding at January 1, 2026 | $ | |||||||||||
| Granted | ||||||||||||
| Exercised | — | — | — | |||||||||
| Forfeited | ( | ) | — | |||||||||
| Outstanding at September 30, 2026 | $ | |||||||||||
| Exercisable at September 30, 2026 | $ | |||||||||||
As
of September 30, 2026, vested outstanding stock options had
The Company recognizes compensation expense for stock option awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period.
The following assumptions were used to calculate the grant date fair value of awards issued during the nine months ended September 30, 2026 and 2025:
Schedule of Assumptions used in Share-based Compensation
| 2026 | 2025 | |||||||
| Volatility | % | % | ||||||
| Risk-free interest rate | % | % | ||||||
| Dividend yield | % | % | ||||||
| Expected term | ||||||||
The Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. Accordingly, the Company has elected to use the “simplified method” to estimate the expected term of its share-based awards. The simplified method computes the expected term as the sum of the award’s vesting term plus the original contractual term divided by two.
The Company estimated the expected volatility input for the Black-Scholes model using the historical volatility of its own publicly traded common stock over a period commensurate with the expected term of the option.
Restricted stock awards
Effective
February 12, 2026, the Company granted an aggregate of
| 27 |
| Table of Contents |
The following table summarizes the Company’s restricted stock awards activity for the nine months ended September 30, 2026:
Schedule of Restricted Stock Units Granted
| Weighted | ||||||||
| Average | ||||||||
| Number of | Grant Date | |||||||
| Units | Fair Value | |||||||
| Outstanding at January 1, 2026 | $ | |||||||
| Granted | ||||||||
| Exercised and converted to common shares | ( | ) | ||||||
| Forfeited | ( | ) | ||||||
| Outstanding at September 30, 2026 | $ | |||||||
| Exercisable at September 30, 2026 | $ | |||||||
Compensation
expense will be recognized ratably over the total vesting schedule. The Company will periodically adjust the cumulative compensation
expense for forfeited awards. The Company recognizes the reversal of any previously recognized compensation expense on forfeited awards
in the period the awards are forfeited. As of September 30, 2026, there was $
Share-based
compensation of $
Warrants
The following table shows a summary of common stock warrants through September 30, 2026:
Schedule of Common Stock Warrants
| Weighted | Weighted | |||||||||||
| Average | Average | |||||||||||
| Number of | Exercise | Contractual | ||||||||||
| Warrants | Price | Term in Years | ||||||||||
| Outstanding at January 1, 2026 | $ | |||||||||||
| Granted | ||||||||||||
| Expired | ( | ) | — | |||||||||
| Outstanding at September 30, 2026 | $ | |||||||||||
| Exercisable at September 30, 2026 | $ | |||||||||||
As
of September 30, 2026 and 2025, vested outstanding warrants had $
16. Commitments and Contingencies
Partnership Advance
On
July 14, 2025, the Company expanded its partnership with STADA Arzneimittel AG (“STADA”), a European leader in consumer health.
The expansion included a $
License agreement
Under
the License Agreement described in Note 1, the Company may be required to make contingent milestone payments of up to $
| 28 |
| Table of Contents |
Litigation
Except as described below, the Company may be subject to legal proceedings and claims that arise in the ordinary course of business. Management is not currently aware of any matters that will or may have a material effect on the financial position, results of operations, or cash flows of the Company.
On
April 27, 2026, Bezalel Partners, LLC (“Bezalel”) commenced an arbitration proceeding against the Company before JAMS, asserting
claims for breach of contract and declaratory relief arising from a Finder’s Fee Agreement, dated July 29, 2024, as amended. Bezalel
alleges that it is entitled to a “Transaction Fee” in excess of $
On
September 15, 2026, the Company’s former President and Chief Executive Officer, who was also a former member of the
Company’s Board of Directors, filed a complaint against the Company in the United States District Court for the Southern
District of New York. The complaint alleges breach of his Executive Employment Agreement and certain other allegations in connection
with the termination of his employment effective August 21, 2026. The Company disputes the plaintiff’s claims and intends to
defend the action vigorously. As of September 30, 2026, the Company had accrued $
17. Concentrations of Risk
For
the nine months ended September 30, 2026, the Company had one customer that approximated
The
Company had four customers with accounts receivable balances that were
The
Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash, cash equivalents,
restricted cash, and marketable securities. Cash balances are maintained principally at major U.S. financial institutions and are insured
by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. As of September 30, 2026, there is a $
18. Related Party Transactions
Accounts payable – related party
As
of September 30, 2026 and December 31, 2025, the Company had outstanding balances of $
Brian
J. Kieser, the Company’s Interim Chief Executive Officer since August 21, 2026 and a member of its Board of Directors, is the Chief
Executive Officer and sole owner of Sequence LifeScience, Inc. (“Sequence”). On April 17, 2026, prior to Mr. Kieser’s
appointment to the Company’s Board of Directors, Sequence purchased an unsecured convertible promissory note in the original principal
amount of $
| 29 |
| Table of Contents |
Sales Representative Obligations
In
connection with the Company’s April 2026 transaction with Celularity Inc., the Company assumed obligations to two sales representatives. On September 10, 2026, Sequence issued
promissory notes directly to the sales representatives in the principal amounts of $
19. Subsequent Events
In accordance with ASC 855, Subsequent Events, the Company evaluated subsequent events after September 30, 2026, through the date these condensed consolidated financial statements were issued and has determined that, other than already disclosed or noted below, no further transactions or events have occurred that require recognition or disclosure in the condensed consolidated financial statements.
Recapitalization and Proposed Merger
On
November 10, 2026, the Company entered into and closed Note Amendment and Conversion Agreements with holders of approximately $
The proposed merger would combine the businesses of Fountainhead LifeSciences and its affiliates, including Sequence and NVISION Biomedical Technologies, Inc. (“Fountainhead”), with the Company in exchange for 45% to 50% of the Company’s fully diluted shares. Fountainhead is an affiliate of Mr. Kieser, the Company’s Interim Chief Executive Officer and a director, so the merger would be a related party transaction. Mr. Kieser, Sequence and certain other directors and officers hold notes and participated in the financing. No definitive agreement for the merger has been entered into, and there is no assurance that it will be completed. The Company is evaluating the accounting for these transactions, including the modification of the notes and warrants, and cannot yet estimate their effect on its financial statements.
Potential Sale of Consumer Brands
In October 2026, the Company began marketing its Silly George and Kenkoderm brands for sale. No definitive agreement has been entered into with respect to either or both brands, and the Company does not expect a sale to have a material effect on its results.
| 30 |
| Table of Contents |
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis are intended to help investors understand our business, financial condition, results of operations, liquidity and capital resources. You should read this discussion in conjunction with our condensed consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q.
The statements in this discussion regarding industry outlook, expectations regarding our future performance, liquidity and capital resources and other non-historical statements are forward-looking statements. These forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, the risks and uncertainties described in “Forward-Looking Statements.” Actual results may differ materially from those contained in any forward-looking statements.
Forward-Looking Statements
This Quarterly Report on Form 10-Q contains “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment and regulation. Words such as “may,” “should,” “could,” “would,” “predict,” “potential,” “continue,” “expect,” “anticipate,” “future,” “intend,” “plan,” “believe,” “estimate,” and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will actually be achieved. Forward-looking statements are based on information we have when those statements are made or our management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to:
| ● | our ability to continue as a going concern; | |
| ● | inadequate capital; | |
| ● | inadequate or an inability to raise sufficient capital to execute our business plan; | |
| ● | our ability to comply with current good manufacturing practices; | |
| ● | loss or retirement of key executives; | |
| ● | our plans to make significant additional outlays of working capital before we expect to generate significant revenues and the uncertainty regarding when we will begin to generate significant revenues, if we are able to do so; | |
| ● | adverse economic conditions and/or intense competition; | |
| ● | loss of a key customer or supplier; | |
| ● | entry of new competitors; | |
| ● | adverse federal, state and local government regulation; | |
| ● | technological obsolescence of our manufacturing process and equipment; |
| ● | technical problems with our research and products; | |
| ● | risks of mergers and acquisitions including the time and cost of implementing transactions and the potential failure to achieve expected gains, revenue growth or expense savings; | |
| ● | price increases for supplies and components; | |
| ● | our ability to complete the proposed merger with Fountainhead LifeSciences, which is a related-party transaction, and the related conversion of our convertible notes; |
| 31 |
| Table of Contents |
| ● | our ability to maintain the listing of our common stock on The Nasdaq Capital Market; | |
| ● | our dependence on Celularity and our ability to realize the anticipated benefits of the Celularity Transaction; | |
| ● | potential events of default under our convertible notes; | |
| ● | the outcome of pending and threatened legal proceedings; and | |
| ● | the inability to carry out our business plans. |
For a discussion of these and other risks that relate to our business and investing in shares of our common stock, you should carefully review the risks and uncertainties described elsewhere in this Quarterly Report on Form 10-Q. The forward-looking statements contained in this Quarterly Report on Form 10-Q are expressly qualified in their entirety by this cautionary statement. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
There may be other factors that may cause our actual results to differ materially from the forward-looking statements, including factors disclosed under the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Quarterly Report on Form 10-Q. You should evaluate all forward-looking statements made in this Quarterly Report on Form 10-Q in the context of these risks and uncertainties.
No assurance can be given that any goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events, except as required by law.
Overview
We manufacture high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. We specialize in custom gels by capitalizing on proprietary manufacturing technologies. We distribute our products as a contract manufacturer, supplying our gels to third parties who incorporate them into their own products. We also have a line of branded consumer products sold direct to consumers and custom and white label opportunities, which focuses on combining our gels with proprietary branded products and white label opportunities. All of our gel products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Together, these technologies enable us to produce gels that can satisfy rigid tolerance specifications with respect to a wide range of physical characteristics (e.g., thickness, water content, adherence, absorption, moisture vapor transmission rate a measure of the passage of water vapor through a substance] and release rate) while maintaining product integrity. Additionally, we have the manufacturing ability to offer broad choices in the selection of liners onto which the gels are coated. Consequently, we and our customers are able to determine tolerances in moisture vapor transmission rate and active ingredient release rates while personalizing color and texture. Our joint venture with CG Laboratories, Inc. called CG Converting and Packaging, LLC, which is located in Granbury, Texas in which we own a 50% interest, allows us to expand our ability to deliver finished goods to our growing customer base.
Since April 2026, following our acquisition of an exclusive license to, and certain assets related to, Celularity portfolio of commercial-stage regenerative biomaterials (see Note 1, “License and Acquisition of Celularity, Inc.’s Portfolio of Commercial-stage Regenerative Biomaterials”), we also market and sell biomaterial products used in tendon repair, soft tissue reconstruction and bone regeneration under the brand name “BioNx.”
Lines of Business
We have five distinct lines of business; Contract Manufacturing, Custom & White Label, Consumer Branded Products, Medical Devices/Other, and BioNx.
Contract Manufacturing
Customers order rolls of gel (“rollstock”). The rollstock is shipped to our customers, which they package into finished goods. Historically, this has been the Company’s primary source of revenue.
| 32 |
| Table of Contents |
Custom & White Label
These products often infuse various ingredients into our base gel to develop unique product offerings to satisfy market demand (e.g. aloe infused into the gel for a beauty mask). The rollstock is converted and packaged into salable units. The finished goods are shipped to the customer, who is ultimately responsible for product distribution. Frequently these products started as development deals, in which the customer paid the company a small fee to develop a specific product. Once completed, the customer places a large order for newly developed product.
Consumer Branded Products
These products are finished goods marketed and sold directly to the customer by the Company through online and retail channels. We are responsible for sales, marketing, and distribution. The products we sell under our MedaGel brand primarily relate to healthcare over-the-counter (“OTC”) remedy solutions, such as blister and pain applications. In December 2023 we added a second consumer product brand when we completed the purchase of the Kenkoderm brand. The Kenkoderm skincare line was originally developed by a dermatologist to provide gentle to the skin products for consumer with psoriasis. In May 2024, we added our third consumer product brand with the purchase of the Silly George brand. Silly George is a beauty brand primarily focused on false eyelashes and other eye related products. We continue to look for additional potential acquisitions as part of our consumer product “roll-up” strategy.
Biomaterial Products
These products are licensed from the Celularity transaction, as disclosed in Note 1, and the acquired portfolio includes 6 established products with over a decade of clinical use and existing reimbursement coverage. We are responsible for sales, marketing and distribution.
Medical Devices/Other
Medical Devices are a hybrid business, combining elements of Custom & White Label and Consumer Branded Products. Medical Devices, which are not yet marketed, are expected to be distributed through strategic partnerships. We will manufacture and possibly convert/package the device while the strategic partner brings the product to market. Small market Medical Devices could be launched by us, but also be offered to a distributor to reach the full scale of the market.
Other includes freight charged to customers who purchase the Company’s branded consumer products through their Shopify stores.
Results of Operations
The following sections discuss and analyze the changes in the significant line items in the accompanying condensed consolidated statements of operations for the comparison periods identified.
Comparison of the Three Months ended September 30, 2026 and 2025 ($ in thousands)
Revenues, net
| Three Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Revenues, net | $ | 3,179 | $ | 2,934 | ||||
For the three months ended September 30, 2026 revenues were $3,179 and increased by $245, or 8.4%, when compared to $2,934 for the three months ended September 30, 2025. The increase in our overall revenues was primarily due to new Biomaterial product revenue of $881, partially offset by decreases of $442 in Consumer Branded Products revenue and $171 in Contract Manufacturing revenue.
Cost of revenues are as follows for the three months ended September 30, 2026 and 2025 ($ in thousands):
| Three Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Cost of revenues | $ | 2,054 | $ | 1,691 | ||||
Cost of revenues increased by $363, or 21.5%, to $2,054 for the three months ended September 30, 2026, as compared to $1,691 for the three months ended September 30, 2025. The increase in cost of revenues is primarily aligned with the increase in sales from the new Biomaterial products, combined with increased freight and royalty costs.
| 33 |
| Table of Contents |
Gross profit
Our gross profit was $1,125 for the three months ended September 30, 2026 compared to a gross profit of $1,243 for the three months ended September 30, 2025. The decrease of $118 in gross profit recorded for the three months ended September 30, 2026, as compared to September 30, 2025, was primarily due to the initial Biomaterial product sales at lower margin combined with higher inventory write off, freight and royalty costs. Gross margin was 35.4% for the three months ended September 30, 2026 compared to 42.4% for the three months ended September 30, 2025.
Selling, general and administrative expenses. Selling, general and administrative expenses are as follows for the three months ended September 30, 2026 and 2025 ($ in thousands):
| Three Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Selling, general and administrative expenses | $ | 3,664 | $ | 1,961 | ||||
Selling, general and administrative expenses increased by $1,703 or 86.8%, to $3,664 for the three months ended September 30, 2026, as compared to $1,961 for the three months ended September 30, 2025. The increase in Selling, general and administrative expenses is primarily attributable to $702 in costs related to establishing and running the BioNx Surgical division to sell Biomaterial products, along with $1,134 in amortization of the intangible asset related to the Celularity license agreement.
Research and development expenses
Research and development expenses were $0 and $7 for the three months ended September 30, 2026 and September 30, 2025. Research and development expenses are related to research costs incurred for potential products for existing or new customers.
Comparison of the Nine Months ended September 30, 2026 and 2025 ($ in thousands)
Revenues, net
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Revenues, net | $ | 9,515 | $ | 8,625 | ||||
For the nine months ended September 30, 2026 revenues were $9,515 and increased by $890, or 10.3%, when compared to $8,625 for the nine months ended September 30, 2025. The increase in our overall revenues was primarily due to $1,695 in sales of Biomaterial products, partially offset by a $730 decline in Consumer Branded Products revenue.
Cost of revenues are as follows for the nine months ended September 30, 2026 and 2025 ($ in thousands):
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Cost of revenues | $ | 6,221 | $ | 4,935 | ||||
Cost of revenues increased by $1,286, or 26.1%, to $6,221 for the nine months ended September 30, 2026, as compared to $4,935 for the nine months ended September 30, 2025. The increase in cost of revenues is primarily aligned with increase in sales combined with increased inventory write-off, freight and royalty costs.
Gross profit
Our gross profit was $3,294 for the nine months ended September 30, 2026 compared to a gross profit of $3,690 for the nine months ended September 30, 2025. The decrease of $396 in gross profit recorded for the nine months ended September 30, 2026, as compared to September 30, 2025 was primarily due to the initial Biomaterial product sales at lower margin combined with higher inventory write off, freight and royalty costs. Gross margin was 34.6% for the nine months ended September 30, 2026 compared to 42.8% for the nine months ended September 30, 2025.
| 34 |
| Table of Contents |
Selling, general and administrative expenses. Selling, general and administrative expenses are as follows for the nine months ended September 30, 2026 and 2025 ($ in thousands):
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Selling, general and administrative expenses | $ | 9,277 | $ | 5,820 | ||||
Selling, general and administrative expenses increased by $3,457, or 59.4%, to $9,277 for the nine months ended September 30, 2026, as compared to $5,820 for the nine months ended September 30, 2025. The increase in Selling, general and administrative expenses is primarily attributable to $1,359 in costs related to establishing and running the BioNx Surgical division to sell Biomaterial products, along with $1,890 in amortization of the intangible asset related to the Celularity license agreement.
Research and development expenses
Research and development expenses increased by $12 to $20 for the nine months ended September 30, 2026 from $8 for the nine months ended September 30, 2025. Research and development expenses are related to research costs incurred for potential products for existing or new customers.
Liquidity and Capital Resources ($ in thousands)
Cash Flow (in thousands)
| September 30, | September 30, | |||||||
| 2026 | 2025 | |||||||
| Net cash used in operating activities | $ | (3,832 | ) | $ | (1,592 | ) | ||
| Net cash provided by (used in) investing activities | (6,620 | ) | (28 | ) | ||||
| Net cash provided by financing activities | 10,052 | 1,671 | ||||||
| Net increase (decrease) in cash and cash equivalents | (400 | ) | 51 | |||||
| Cash and cash equivalents at beginning of year | 1,058 | 1,807 | ||||||
| Cash and cash equivalent at end of quarter | $ | 658 | $ | 1,858 | ||||
As of September 30, 2026, we had $658 of cash and restricted cash, of which $278 was unrestricted, compared to $1,058 of cash and restricted cash, of which $317 was unrestricted, at December 31, 2025. Net cash used in operating activities was $5,124 and $1,592 for the nine months ended September 30, 2026 and 2025, respectively.
Net cash used in investing activities was $6,620 and $28 for the nine months ended September 30, 2026 and 2025, respectively. The increase was primarily due to the $6,503 cash payment for the acquisition of an exclusive license and related assets from Celularity, as well as $117 of capital expenditures, compared to $28 in the prior-year period.
Net cash provided by financing activities for the nine months ended September 30, 2026 was $10,052 and was attributable to net proceeds from convertible notes payable of $11,140 offset by principal payments of notes payable and principal payments of financing lease liabilities of $906 and debt financing costs of $182. Net cash provided by financing activities for the nine months ended September 30, 2025 was $1,671 and was attributable to the proceeds from rights offerings and stock issuances of $963, proceeds from STADA of $1,000, offset by principal payments of notes payable of $71, principal payments of financing lease liabilities of $43, and payment of contingent consideration of $178.
At September 30, 2026, current assets totaled $4,936 and current liabilities totaled $10,626 as compared to current assets totaling $4,338 and current liabilities totaling $2,956 at December 31, 2025. As a result, we had negative working capital of $5,690 at September 30, 2026, compared to a working capital of $1,382 at December 31, 2025. The decrease in the working capital as of September 30, 2026 is primarily attributable to the loss from operations of $6,003, an increase in non-cash derivative liability of $4,584 and proceeds from issuance of convertible debt, exclusive of Celularity financing, of $2,556.
| 35 |
| Table of Contents |
We have never declared or paid any cash dividends on our common stock. For the foreseeable future, we anticipate that all available funds and any earnings generated in our business will be used to finance the growth of our business and will not be paid out as dividends to our shareholders. Any future determination related to our dividend policy will be made at the discretion of our Board of Directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our Board of Directors may deem relevant.
We expect to continue incurring losses for the near-term future. Our ability to continue to operate as a going concern in the long term is dependent upon our ability to manage and grow our current products and to ultimately achieve profitable operations. Management may consider various options to raise capital to fund potential acquisitions through equity or debt offerings. There can be no assurances, however, that management will be able to obtain sufficient additional funds, if needed, or that such funds, if available, will be obtained on terms satisfactory to us. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should we be unable to continue as a going concern.
Additionally, it is reasonably possible that estimates made in the financial statements have been, or will be, materially and adversely impacted in the near term as a result of these conditions, including the recoverability of long-lived assets.
Material Cash Requirements and Recent Developments
As of September 30, 2026, we had $278 of unrestricted cash. Our material cash requirements over the next twelve months include, among other things, the remaining $1,798 of cash consideration payable to Celularity under the License Agreement, amounts we have agreed to reimburse to Sequence and Mr. Kieser in respect of the Sales Representative obligations described in Note 18 to our condensed consolidated financial statements, interest on our convertible notes to the extent not paid in shares, and the costs of the legal proceedings described in Note 16. On November 10, 2026, we entered into and closed the Note Amendment and Conversion Agreements and the securities purchase agreement described in Note 19, receiving gross proceeds of approximately $1.2 million. Upon completion of the proposed merger with Fountainhead, holders of approximately $14.1 million in principal amount of our convertible notes would convert their notes into common stock, which would substantially reduce our indebtedness. No definitive agreement for the merger has been entered into, and there can be no assurance that the merger will be completed. Even if these transactions are completed, we expect that we will need to raise additional capital to fund our operations.]
Off Balance Sheet Arrangements
As of September 30, 2026, we had no off-balance sheet arrangements in the nature of guarantee contracts, retained or contingent interests in assets transferred to entities (or similar arrangements serving as credit, liquidity or market risk support to entities for any such assets), or obligations (including contingent obligations) arising out of variable interests in entities providing financing, liquidity, market risk or credit risk support to us, or that engage in leasing, hedging or research and development services with us.
Critical Accounting Policies and Estimates
The preparation of our accompanying condensed consolidated financial statements in accordance with generally accepted accounting principles is based on the selection and application of accounting policies that require us to make significant estimates and assumptions about the effects of matters that are inherently uncertain. We consider the accounting policies discussed below to be critical to the understanding of our Financial Statements. Actual results could differ from our estimates and assumptions, and any such differences could be material to our Financial Statements.
| 36 |
| Table of Contents |
Share-based compensation – We utilize share-based compensation in the form of incentive stock options. The fair values of incentive stock option award grants are estimated as of the date of grant using a Black-Scholes option valuation model. Compensation expense is recognized in the statements of operations on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting. The expected term of the awards granted is estimated using the simplified method which computes the expected term as the sum of the award’s vesting term plus the original contractual term divided by two.
Black Scholes Inputs - The fair value of each stock option award and warrant issued was estimated on the date of grant using a Black-Scholes option-valuation model, which requires management to make certain assumptions regarding: (i) fair value of the common stock that underlies the stock option; (ii) the expected volatility in the market price of our common stock; (iii) dividend yield; (iv) risk-free interest rates; and (v) the period of time employees are expected to hold the award prior to exercise (referred to as the expected term). Under the Black-Scholes option-valuation model, entities typically estimate the expected volatility based on historical volatilities of the entity’s own common stock. Based on the lack of historical data of volatility for the Company’s common stock, the Company based its estimate of expected volatility on a weighted average of the historical volatility of comparable public companies that manufacture similar products and are similar in size, stage of life cycle, and financial leverage. The fair value of the common stock that underlies the stock option is estimated by the Company considering the price of the most recent issuance of the Company’s common stock. The dividend yield is based upon the assumption that the Company will not declare a dividend over the life of the options. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for bonds with maturities consistent with the expected term of the related award.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As a smaller reporting company, we are not required to provide the information required by this Item.
ITEM 4. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures.
As of September 30, 2026, we conducted an evaluation of the effectiveness of our “disclosure controls and procedures” (“Disclosure Controls”), as defined by Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Disclosure Controls evaluation was done under the supervision and with the participation of management, including our chief executive officer and chief financial officer. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon this evaluation, our chief executive officer and chief financial officer have concluded that our Disclosure Controls and Procedures were not effective as of September 30, 2026, due to material weaknesses in our internal control over financial reporting, which are described below.
Specifically, management has concluded that its internal control over financial reporting was not effective as of September 30, 2026 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with accounting principles generally accepted in the United States of America due to not maintaining proper segregation of duties, including: (i) we have not designed controls to ensure all accounting journal entries are reviewed and approved and (ii) we have one individual in our accounting department who has “super user” access and security administration rights to the financial reporting systems.
To remediate these material weaknesses, we are working to do the following: (i) implementing appropriate controls for accounting journal entry approvals, including the approval of our chief financial officer, and (ii) either actively monitoring any accounting user with elevated rights or assigning another employee outside of an accounting and reporting role with elevated access. We will not be able to fully remediate the material weakness until the actions discussed above have been implemented and operated effectively for a sufficient period of time.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting during the fiscal quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| 37 |
| Table of Contents |
PART II – OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
Except as described below, from time to time, we may become involved in lawsuits, investigations and claims that arise in the ordinary course of business. As of the date of this Quarterly Report on Form 10-Q, we are not a party to any litigation whereby the outcome of such litigation, if determined adversely to us, would materially affect our financial position, results of operations or cash flows.
On April 27, 2026, Bezalel Partners, LLC commenced an arbitration proceeding against the Company before JAMS, asserting claims for breach of contract and declaratory relief arising from a Finder’s Fee Agreement and seeking damages in excess of $1,750,000, plus interest, attorneys’ fees and costs. See Note 16 to the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information regarding this proceeding.
On September 15, 2026, the Company’s former President and Chief Executive Officer, who was also a former member of the Company’s Board of Directors, filed a complaint against the Company in the United States District Court for the Southern District of New York. The complaint alleges breach of his Executive Employment Agreement and certain other allegations in connection with the termination of his employment effective August 21, 2026. The Company disputes the plaintiff’s claims and intends to defend the action vigorously. As of September 30, 2026, the Company had accrued $375 thousand, included in accrued expenses and other current liabilities related to this matter. The accrual is not an admission of liability. The Company is unable to estimate any reasonably possible loss in excess of the amount accrued. Litigation is inherently uncertain.
ITEM 1A. RISK FACTORS
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our 2025 Annual Report on Form 10-K, which could materially affect our business, financial condition or future results. Except as set forth below and in Part II, Item 1A of our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026, there have been no material changes to the risk factors that were included in the Form 10-K.
We have incurred substantial indebtedness under convertible notes issued in 2026, which could adversely affect our liquidity and result in significant dilution to our stockholders.
As of September 30, 2026, we had $14.9 million of convertible notes payable outstanding, issued in private placements completed in April, May and July 2026, including the $5.0 million Celularity Note. These notes bear interest at 10% per annum (18% upon an event of default) and are convertible into shares of our common stock at conversion prices subject to downward adjustment. Our ability to service this indebtedness depends on our future operating performance, and our failure to make required payments or comply with applicable covenants could result in an event of default, which could have a material adverse effect on our business and financial condition and cause us to cease operations. Conversion of these notes and exercise of the related warrants will also result in substantial dilution to our existing stockholders.
Our license and acquisition of assets from Celularity may not achieve the anticipated benefits, and we may be required to make significant additional contingent payments.
In April 2026, we completed the acquisition of an exclusive license to Celularity’s commercial-stage regenerative biomaterials portfolio for aggregate upfront consideration of $13.3 million, and we may be required to pay up to an additional $20.0 million in contingent milestone payments if certain commercial milestones are achieved. The anticipated benefits of this transaction, including the successful commercialization of the licensed products under our BioNx brand, may not be realized on the timeline we expect, or at all, and integrating these products and technologies may divert management attention and require significant additional expenditures.
| 38 |
| Table of Contents |
The proposed recapitalization and merger with Fountainhead LifeSciences, an affiliate of our Interim Chief Executive Officer, may not be completed, and if completed, will result in substantial dilution and a significant concentration of ownership.
In November 2026, we amended approximately $14.1 million in principal amount of our convertible notes to provide for their conversion into common stock at $5.50 per share upon completion of a proposed merger with Fountainhead LifeSciences, and we sold shares of common stock and warrants in a private placement. Fountainhead is an affiliate of Brian Kieser, our Interim Chief Executive Officer and a director, who, together with Sequence LifeScience, Inc., holds $6.5 million in principal amount of our convertible notes, and the owners of Fountainhead would receive 45% to 50% of our fully diluted shares. No definitive merger agreement has been entered into, and the merger is subject to, among other things, negotiation of definitive terms, approval by a special committee of independent directors, receipt of a fairness opinion and the approval of our stockholders. If the merger is not completed by March 31, 2027 (subject to extension), the notes will not convert and will remain outstanding, and the shares sold in the private placement will be exchanged for convertible notes. If the transactions are completed, our existing stockholders will experience substantial dilution, and Mr. Kieser and his affiliates will be in a position to exert significant influence over matters requiring stockholder approval. Mr. Kieser’s interests in these transactions may differ from those of our other stockholders.
We may be unable to maintain the listing of our common stock on The Nasdaq Capital Market.
In April 2026, we received a deficiency notice from Nasdaq relating to the minimum bid price requirement, and on October 12, 2026 we effected a 1-for-20 reverse stock split to regain compliance, which Nasdaq confirmed on October 26, 2026. There can be no assurance that we will continue to satisfy the minimum bid price requirement or Nasdaq’s other continued listing requirements, including the minimum stockholders’ equity requirement, or that the transactions described above will not raise additional listing compliance matters. The reverse stock split may also reduce the liquidity of our common stock. A delisting of our common stock could adversely affect its liquidity and market price and our ability to raise capital, and could constitute an event of default under our convertible notes.
We are party to legal proceedings that could result in significant costs and liabilities.
We are defending an arbitration brought by Bezalel Partners, LLC seeking a transaction fee in excess of $1.75 million, plus interest and fees, and a lawsuit brought by our former Chief Executive Officer seeking severance and other damages, and we have received other claims and demands relating to our business and the Celularity Transaction. Litigation is costly and diverts management attention, and an adverse outcome in any of these matters could have a material adverse effect on our liquidity and financial condition.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
(a) Sales of Unregistered Securities during the nine months ended September 30, 2026
Other than as previously reported on the Company’s Current Reports on Form 8-K filed with the Securities and Exchange Commission, the Company did not sell any unregistered securities during the three months ended September 30, 2026.
(b) Issuer Repurchases of Securities during the nine months ended September 30, 2026
The Company did not repurchase any of its securities during the nine months ended September 30, 2026.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
Rule 10b5-1 Trading Plans.
During
the three months ended September 30, 2026, no director or officer of the Company
| 39 |
| Table of Contents |
ITEM 6. EXHIBITS
See “Index to Exhibits” for a description of our exhibits.
Index to Exhibits
| Exhibit No. | Description | |
| 3.1 | Certificate of Incorporation of AquaMed Technologies, Inc. (incorporated by reference to Exhibit 3.1 to Form S-1, filed with the SEC on January 9, 2019). | |
| 3.2 | Certificate of Amendment to Certificate of Incorporation of AquaMed Technologies, Inc. (incorporated by reference to Exhibit 3.2 to Form S-1, filed with the SEC on January 9, 2019). | |
| 3.3 | Amended and Restated Certificate of Incorporation of AquaMed Technologies, Inc. (incorporated by reference to Exhibit 3.3 to Amendment No. 1 to Form S-1, filed with the SEC on March 11, 2019). | |
| 3.4 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of AquaMed Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on November 14, 2019) | |
| 3.5 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of NexGel, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on May 29, 2020) | |
| 3.6 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of NexGel, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on August 2, 2021) | |
| 3.7 | Amended and Restated Bylaws of AquaMed Technologies, Inc. (incorporated by reference to Exhibit 3.5 to Amendment No. 1 to Form S-1, filed with the SEC on March 11, 2019). | |
| 31.1* | Certification of Chief Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002. | |
| 31.2* | Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002. | |
| 32.1* | Certification of Chief Executive Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 32.2* | Certification of Chief Financial Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 101* | The following materials from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2026, formatted in iXBRL (Inline eXtensible Business Reporting Language), (i) Balance Sheets, (ii) Statements of Operations, (iii) Statements of Stockholders’ Equity, (iv) Statements of Cash Flows, and (v) Notes to the Financial Statements. | |
| 104* | Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit 101). |
| * | Filed herewith. |
| 40 |
| Table of Contents |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| NEXGEL, INC. | ||
| Date: November 13, 2026 | By: | /s/ Brian Kieser |
| Name: | Brian Kieser | |
| Title: | Interim Chief Executive Officer | |
| (Principal Executive Officer) | ||
| By: | /s/ Ian Blackman | |
| Name: | Ian Blackman | |
| Title: | Chief Financial Officer | |
| (Principal Financial Officer) | ||
| 41 |